{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:27:32Z","timestamp":1783643252600,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40618-018-0931-z","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T02:43:13Z","timestamp":1533782593000},"page":"419-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["PETC\/CT with 18F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism"],"prefix":"10.1007","volume":"42","author":[{"given":"I.","family":"Bossert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chytiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hodolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chiovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"key":"931_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1210\/jc.2008-1763","volume":"94","author":"JP Bilezikian","year":"2009","unstructured":"Bilezikian JP, Khan AA, Potts JT, Hyperthyroidism TIWotMoAP (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335\u2013339. \n                    https:\/\/doi.org\/10.1210\/jc.2008-1763","journal-title":"J Clin Endocrinol Metab"},{"key":"931_CR2","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1210\/jc.2013-1300","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98:2734\u20132741. \n                    https:\/\/doi.org\/10.1210\/jc.2013-1300","journal-title":"J Clin Endocrinol Metab"},{"key":"931_CR3","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1210\/jc.2006-2802","volume":"92","author":"H Lowe","year":"2007","unstructured":"Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92:3001\u20133005. \n                    https:\/\/doi.org\/10.1210\/jc.2006-2802","journal-title":"J Clin Endocrinol Metab"},{"key":"931_CR4","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1210\/jc.2014-4432","volume":"100","author":"G Chen","year":"2015","unstructured":"Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100:2420\u20132424. \n                    https:\/\/doi.org\/10.1210\/jc.2014-4432","journal-title":"J Clin Endocrinol Metab"},{"key":"931_CR5","first-page":"1443","volume":"44","author":"G Mariani","year":"2003","unstructured":"Mariani G, Gulec SA, Rubello D, Boni G, Puccini M, Pelizzo MR et al (2003) Preoperative localization and radioguided parathyroid surgery. J Nucl Med 44:1443\u20131458","journal-title":"J Nucl Med"},{"key":"931_CR6","volume-title":"The parathyroids","author":"G Mariani","year":"2015","unstructured":"Mariani G, Mazzeo S, Rubello DCB (2015) Preoperative localization of abnormal parathyroid glands. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT Jr (eds) The parathyroids, 3rd edn. Elsevier, Oxfrod","edition":"3"},{"key":"931_CR7","volume-title":"Nuclear oncology","author":"F Guidoccio","year":"2017","unstructured":"Guidoccio F, Mazzarri SGM, Mazzeo S (2017) Diagnostic applications of nuclear medicine: parathyroid tumors. In: Strauss H, Mariani G, Volterrani D, Larson S (eds) Nuclear oncology. Springer, Berlin"},{"key":"931_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00268-012-1438-y","volume":"36","author":"TJ Wade","year":"2012","unstructured":"Wade TJ, Yen TW, Amin AL, Wang TS (2012) Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36:761\u2013766. \n                    https:\/\/doi.org\/10.1007\/s00268-012-1438-y","journal-title":"World J Surg"},{"key":"931_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4158\/EP15704.OR","volume":"22","author":"H \u0160iprov\u00e1","year":"2016","unstructured":"\u0160iprov\u00e1 H, Fry\u0161\u00e1k Z, Sou\u010dek M (2016) Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract 22:294\u2013301. \n                    https:\/\/doi.org\/10.4158\/EP15704.OR","journal-title":"Endocr Pract"},{"key":"931_CR10","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1210\/jc.2014-2821","volume":"99","author":"L Michaud","year":"2014","unstructured":"Michaud L, Burgess A, Huchet V, Lef\u00e8vre M, Tassart M, Ohnona J et al (2014) Is 18F-fluorocholine-positron emission tomography\/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab 99:4531\u20134536. \n                    https:\/\/doi.org\/10.1210\/jc.2014-2821","journal-title":"J Clin Endocrinol Metab"},{"key":"931_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s13139-015-0357-x","volume":"50","author":"WM Vorselaars","year":"2016","unstructured":"Vorselaars WM, Kluijfhout WP, Vriens MR, van der Pol CC, Borel Rinkes IH, Valk GD et al (2016) Detection of synchronous parathyroid adenoma and breast cancer with (18)F-Fluorocholine PET-CT. Nucl Med Mol Imaging 50:180\u2013182. \n                    https:\/\/doi.org\/10.1007\/s13139-015-0357-x","journal-title":"Nucl Med Mol Imaging"},{"key":"931_CR12","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00259-014-2837-0","volume":"41","author":"L Lezaic","year":"2014","unstructured":"Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J (2014) 18F-Fluorocholine PET\/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 41:2083\u20132089. \n                    https:\/\/doi.org\/10.1007\/s00259-014-2837-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"931_CR13","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1097\/RLU.0000000000001845","volume":"42","author":"N Thanseer","year":"2017","unstructured":"Thanseer N, Bhadada SK, Sood A, Mittal BR, Behera A, Gorla AKR et al (2017) Comparative effectiveness of ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET\/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med 42:e491\u2013e497. \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000001845","journal-title":"Clin Nucl Med"},{"key":"931_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1590\/S0004-27302010000200004","volume":"54","author":"JP Bilezikian","year":"2010","unstructured":"Bilezikian JP, Silverberg SJ (2010) Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 54:106\u2013109","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"931_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.otohns.2004.10.005","volume":"132","author":"JM Ruda","year":"2005","unstructured":"Ruda JM, Hollenbeak CS, Stack BC (2005) A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 132:359\u2013372. \n                    https:\/\/doi.org\/10.1016\/j.otohns.2004.10.005","journal-title":"Otolaryngol Head Neck Surg"},{"key":"931_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/01.MLG.0000203411.53666.AD","volume":"116","author":"Y Erbil","year":"2006","unstructured":"Erbil Y, Barbaros U, Yanik BT, Salmaslio\u011flu A, Tunaci M, Adalet I et al (2006) Impact of gland morphology and concomitant thyroid nodules on preoperative localization of parathyroid adenomas. Laryngoscope 116:580\u2013585. \n                    https:\/\/doi.org\/10.1097\/01.MLG.0000203411.53666.AD","journal-title":"Laryngoscope"},{"key":"931_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.carj.2016.07.004","volume":"68","author":"S Liddy","year":"2017","unstructured":"Liddy S, Worsley D, Torreggiani W, Feeney J (2017) Preoperative imaging in primary hyperparathyroidism: literature review\u00a0and recommendations. Can Assoc Radiol J 68:47\u201355. \n                    https:\/\/doi.org\/10.1016\/j.carj.2016.07.004","journal-title":"Can Assoc Radiol J"},{"key":"931_CR18","first-page":"822","volume":"39","author":"A Vattimo","year":"1998","unstructured":"Vattimo A, Bertelli P, Cintorino M, Burroni L, Volterrani D, Vella A et al (1998) H\u00fcrthle cell tumor dwelling in hot thyroid nodules: preoperative detection with technetium-99m-MIBI dual-phase scintigraphy. J Nucl Med 39:822\u2013825","journal-title":"J Nucl Med"},{"key":"931_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00423-016-1425-0","volume":"401","author":"WP Kluijfhout","year":"2016","unstructured":"Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT et al (2016) Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg 401:925\u2013935. \n                    https:\/\/doi.org\/10.1007\/s00423-016-1425-0","journal-title":"Langenbecks Arch Surg"},{"key":"931_CR20","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00259-015-3130-6","volume":"42","author":"D Deandreis","year":"2015","unstructured":"Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F et al (2015) 18Fluorocholine PET\/CT in parathyroid carcinoma: a new tool for disease staging? Eur J Nucl Med Mol Imaging 42:1941\u20131942. \n                    https:\/\/doi.org\/10.1007\/s00259-015-3130-6","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0931-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0931-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0931-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T19:08:17Z","timestamp":1568747297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0931-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0931-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Irene Bossert declares that she has no conflict of interest. Spyridon Chytiris declares that he has no conflict of interest. Marina Hodolic is Clinical Research Supervisor, Iason, Graz, Austria. Laura Croce declares that she has no conflict of interest. Luigi Mansi declares that he has no conflict of interest. Luca Chiovato declares that he has no conflict of interest. Giuliano Mariani declares that he has no conflict of interest. Giuseppe Trifir\u00f2 declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}